
Sarah Warren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2138915/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gene expression markers of Tumor Infiltrating Leukocytes. , 2017, 5, 18.		572
2	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344
3	The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. Journal of Translational Medicine, 2019, 17, 357.	4.4	88
4	Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic. Biomedicines, 2018, 6, 14.	3.2	66
5	CD56dim CD16â^' Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α. Frontiers in Immunology, 2019, 10, 14.	4.8	41
6	Dissecting the Immune Landscape of Acute Myeloid Leukemia. Biomedicines, 2018, 6, 110.	3.2	32
7	Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Science Translational Medicine, 2022, 14, eabg8402.	12.4	28
8	Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform. Scientific Reports, 2021, 11, 3712.	3.3	21
9	Impact of checkpoint blockade on cancer vaccine–activated CD8+ T cell responses. Journal of Experimental Medicine, 2020, 217, .	8.5	20
10	Simultaneous, Multiplexed Detection of RNA and Protein on the NanoString® nCounter® Platform. Methods in Molecular Biology, 2018, 1783, 105-120.	0.9	17
11	A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity. , 2019, 7, 15.		17
12	Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform. Clinical Chemistry, 2021, 67, 554-563.	3.2	12
13	Capturing the complexity of the immune microenvironment of acute myeloid leukemia with 3D biology technology Journal of Clinical Oncology, 2018, 36, 50-50.	1.6	8
14	CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS ONE, 2021, 16, e0245287.	2.5	7
15	A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 518-525.	7.0	7
16	Development of Gene Expression-Based Biomarkers on the nCounter® Platform for Immuno-Oncology Applications. Methods in Molecular Biology, 2020, 2055, 273-300.	0.9	4